First Header Logo Second Header Logo

Connection

Roy Hantgan to Humans

This is a "connection" page, showing publications Roy Hantgan has written about Humans.
Connection Strength

0.316
  1. Hantgan RR, Stahle MC, Lord ST. Dynamic regulation of fibrinogen: integrin aIIbß3 binding. Biochemistry. 2010 Nov 02; 49(43):9217-25.
    View in: PubMed
    Score: 0.018
  2. Hantgan RR, Stahle MC, Horita DA. Entropy drives integrin alphaIIbbeta3:echistatin binding--evidence from surface plasmon resonance spectroscopy. Biochemistry. 2008 Mar 04; 47(9):2884-92.
    View in: PubMed
    Score: 0.015
  3. Hantgan RR, Stahle MC, Connor JH, Connor RF, Mousa SA. AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists. J Thromb Haemost. 2007 Mar; 5(3):542-50.
    View in: PubMed
    Score: 0.014
  4. Sunwook K, Nussbaum MA, Quandt SA, Laurienti PJ, Arcury TA. Effects of Lifetime Occupational Pesticide Exposure on Postural Control Among Farmworkers and Non-Farmworkers. J Occup Environ Med. 2016 Feb; 58(2):133-9.
    View in: PubMed
    Score: 0.013
  5. Jerome WG, Handt S, Hantgan RR. Endothelial cells organize fibrin clots into structures that are more resistant to lysis. Microsc Microanal. 2005 Jun; 11(3):268-77.
    View in: PubMed
    Score: 0.012
  6. Hantgan RR, Stahle MC, Connor JH, Lyles DS, Horita DA, Rocco M, Nagaswami C, Weisel JW, McLane MA. The disintegrin echistatin stabilizes integrin alphaIIbbeta3's open conformation and promotes its oligomerization. J Mol Biol. 2004 Oct 01; 342(5):1625-36.
    View in: PubMed
    Score: 0.012
  7. Mizel SB, West AP, Hantgan RR. Identification of a sequence in human toll-like receptor 5 required for the binding of Gram-negative flagellin. J Biol Chem. 2003 Jun 27; 278(26):23624-9.
    View in: PubMed
    Score: 0.011
  8. Hantgan RR, Lyles DS, Mallett TC, Rocco M, Nagaswami C, Weisel JW. Ligand binding promotes the entropy-driven oligomerization of integrin alpha IIb beta 3. J Biol Chem. 2003 Jan 31; 278(5):3417-26.
    View in: PubMed
    Score: 0.010
  9. Hantgan RR, Stahle MC, Jerome WG, Nagaswami C, Weisel JW. Tirofiban blocks platelet adhesion to fibrin with minimal perturbation of GpIIb/IIIa structure. Thromb Haemost. 2002 May; 87(5):910-7.
    View in: PubMed
    Score: 0.010
  10. Hantgan RR, Rocco M, Nagaswami C, Weisel JW. Binding of a fibrinogen mimetic stabilizes integrin alphaIIbbeta3's open conformation. Protein Sci. 2001 Aug; 10(8):1614-26.
    View in: PubMed
    Score: 0.009
  11. Hantgan RR, Stahle M, Del Gaizo V, Adams M, Lasher T, Jerome WG, McKenzie M, Lyles DS. AlphaIIb's cytoplasmic domain is not required for ligand-induced clustering of integrin alphaIIbbeta3. Biochim Biophys Acta. 2001 Jul 25; 1540(1):82-95.
    View in: PubMed
    Score: 0.009
  12. Hantgan RR, Paumi C, Rocco M, Weisel JW. Effects of ligand-mimetic peptides Arg-Gly-Asp-X (X = Phe, Trp, Ser) on alphaIIbbeta3 integrin conformation and oligomerization. Biochemistry. 1999 Nov 02; 38(44):14461-74.
    View in: PubMed
    Score: 0.008
  13. Hantgan RR, Jerome WG, Hursting MJ. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin. Blood. 1998 Sep 15; 92(6):2064-74.
    View in: PubMed
    Score: 0.008
  14. Hantgan RR, Mousa SA. Inhibition of platelet-mediated clot retraction by integrin antagonists. Thromb Res. 1998 Mar 15; 89(6):271-9.
    View in: PubMed
    Score: 0.008
  15. Hantgan RR, Jerome WG, Handt S. Platelets and endothelial cells act in concert to delay thrombolysis--evidence from an in vitro model of the human occlusive thrombus. Thromb Haemost. 1998 Mar; 79(3):602-8.
    View in: PubMed
    Score: 0.007
  16. Handt S, Jerome WG, Tietze L, Hantgan RR. Plasminogen activator inhibitor-1 secretion of endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot: evidence for a key role of endothelial cells in thrombolytic resistance. Blood. 1996 May 15; 87(10):4204-13.
    View in: PubMed
    Score: 0.007
  17. Hantgan RR, Endenburg SC, Sixma JJ, de Groot PG. Evidence that fibrin alpha-chain RGDX sequences are not required for platelet adhesion in flowing whole blood. Blood. 1995 Aug 01; 86(3):1001-9.
    View in: PubMed
    Score: 0.006
  18. Braaten JV, Jerome WG, Hantgan RR. Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface. Blood. 1994 Feb 15; 83(4):982-93.
    View in: PubMed
    Score: 0.006
  19. Melchior JT, Sawyer JK, Kelley KL, Shah R, Wilson MD, Hantgan RR, Rudel LL. LDL particle core enrichment in cholesteryl oleate increases proteoglycan binding and promotes atherosclerosis. J Lipid Res. 2013 Sep; 54(9):2495-503.
    View in: PubMed
    Score: 0.005
  20. Ferluga S, Hantgan R, Goldgur Y, Himanen JP, Nikolov DB, Debinski W. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase. J Biol Chem. 2013 Jun 21; 288(25):18448-57.
    View in: PubMed
    Score: 0.005
  21. Hantgan RR, Braaten JV, Rocco M. Dynamic light scattering studies of alpha IIb beta 3 solution conformation. Biochemistry. 1993 Apr 20; 32(15):3935-41.
    View in: PubMed
    Score: 0.005
  22. Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. Blood. 1993 Mar 01; 81(5):1290-9.
    View in: PubMed
    Score: 0.005
  23. Burnett LR, Rahmany MB, Richter JR, Aboushwareb TA, Eberli D, Ward CL, Orlando G, Hantgan RR, Van Dyke ME. Hemostatic properties and the role of cell receptor recognition in human hair keratin protein hydrogels. Biomaterials. 2013 Apr; 34(11):2632-40.
    View in: PubMed
    Score: 0.005
  24. Rahmany MB, Hantgan RR, Van Dyke M. A mechanistic investigation of the effect of keratin-based hemostatic agents on coagulation. Biomaterials. 2013 Mar; 34(10):2492-500.
    View in: PubMed
    Score: 0.005
  25. Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz A. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Ra2 tumor-restricted biomarker. Neuro Oncol. 2012 Oct; 14(10):1239-53.
    View in: PubMed
    Score: 0.005
  26. Tsurupa G, Pechik I, Litvinov RI, Hantgan RR, Tjandra N, Weisel JW, Medved L. On the mechanism of aC polymer formation in fibrin. Biochemistry. 2012 Mar 27; 51(12):2526-38.
    View in: PubMed
    Score: 0.005
  27. Lema Tomé CM, Palma E, Ferluga S, Lowther WT, Hantgan R, Wykosky J, Debinski W. Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. J Biol Chem. 2012 Apr 20; 287(17):14012-22.
    View in: PubMed
    Score: 0.005
  28. Riedel TJ, Johnson LC, Knight J, Hantgan RR, Holmes RP, Lowther WT. Structural and biochemical studies of human 4-hydroxy-2-oxoglutarate aldolase: implications for hydroxyproline metabolism in primary hyperoxaluria. PLoS One. 2011; 6(10):e26021.
    View in: PubMed
    Score: 0.005
  29. Giri B, Smaldino PJ, Thys RG, Creacy SD, Routh ED, Hantgan RR, Lattmann S, Nagamine Y, Akman SA, Vaughn JP. G4 resolvase 1 tightly binds and unwinds unimolecular G4-DNA. Nucleic Acids Res. 2011 Sep 01; 39(16):7161-78.
    View in: PubMed
    Score: 0.005
  30. Hantgan RR, Hindriks G, Taylor RG, Sixma JJ, de Groot PG. Glycoprotein Ib, von Willebrand factor, and glycoprotein IIb:IIIa are all involved in platelet adhesion to fibrin in flowing whole blood. Blood. 1990 Jul 15; 76(2):345-53.
    View in: PubMed
    Score: 0.004
  31. Ramsamooj P, Doellgast GJ, Hantgan RR. Inhibition of fibrin(ogen) binding to stimulated platelets by a monoclonal antibody specific for a conformational determinant of GPIIIa. Thromb Res. 1990 Jun 15; 58(6):577-92.
    View in: PubMed
    Score: 0.004
  32. Hantgan RR, Nichols WL, Ruggeri ZM. von Willebrand factor competes with fibrin for occupancy of GPIIb:IIIa on thrombin-stimulated platelets. Blood. 1990 Feb 15; 75(4):889-94.
    View in: PubMed
    Score: 0.004
  33. Tsurupa G, Hantgan RR, Burton RA, Pechik I, Tjandra N, Medved L. Structure, stability, and interaction of the fibrin(ogen) alphaC-domains. Biochemistry. 2009 Dec 29; 48(51):12191-201.
    View in: PubMed
    Score: 0.004
  34. Lewis JC, Johnson C, Ramsamooj P, Hantgan RR. Orientation and specificity of fibrin protofibril binding to ADP-stimulated platelets. Blood. 1988 Dec; 72(6):1992-2000.
    View in: PubMed
    Score: 0.004
  35. Shen K, Sergeant S, Hantgan RR, McPhail LC, Horita DA. Mutations in the PX-SH3A linker of p47phox decouple PI(3,4)P2 binding from NADPH oxidase activation. Biochemistry. 2008 Aug 26; 47(34):8855-65.
    View in: PubMed
    Score: 0.004
  36. Azarov I, He X, Jeffers A, Basu S, Ucer B, Hantgan RR, Levy A, Kim-Shapiro DB. Rate of nitric oxide scavenging by hemoglobin bound to haptoglobin. Nitric Oxide. 2008 Jun; 18(4):296-302.
    View in: PubMed
    Score: 0.004
  37. Hantgan RR. Fibrin protofibril and fibrinogen binding to ADP-stimulated platelets: evidence for a common mechanism. Biochim Biophys Acta. 1988 Jan 18; 968(1):24-35.
    View in: PubMed
    Score: 0.004
  38. Hantgan RR. Localization of the domains of fibrin involved in binding to platelets. Biochim Biophys Acta. 1988 Jan 18; 968(1):36-44.
    View in: PubMed
    Score: 0.004
  39. Ledford AS, Weinberg RB, Cook VR, Hantgan RR, Shelness GS. Self-association and lipid binding properties of the lipoprotein initiating domain of apolipoprotein B. J Biol Chem. 2006 Mar 31; 281(13):8871-6.
    View in: PubMed
    Score: 0.003
  40. O'Flaherty JT, Rogers LC, Paumi CM, Hantgan RR, Thomas LR, Clay CE, High K, Chen YQ, Willingham MC, Smitherman PK, Kute TE, Rao A, Cramer SD, Morrow CS. 5-Oxo-ETE analogs and the proliferation of cancer cells. Biochim Biophys Acta. 2005 Oct 01; 1736(3):228-36.
    View in: PubMed
    Score: 0.003
  41. Hantgan RR. A study of the kinetics and mechanism of ADP-triggered platelet aggregation. Biochim Biophys Acta. 1985 Jul 30; 846(1):64-75.
    View in: PubMed
    Score: 0.003
  42. Hantgan RR, Taylor RG, Lewis JC. Platelets interact with fibrin only after activation. Blood. 1985 Jun; 65(6):1299-311.
    View in: PubMed
    Score: 0.003
  43. Tsurupa G, Veklich Y, Hantgan R, Belkin AM, Weisel JW, Medved L. Do the isolated fibrinogen alphaC-domains form ordered oligomers? Biophys Chem. 2004 Dec 20; 112(2-3):257-66.
    View in: PubMed
    Score: 0.003
  44. Lounes KC, Lefkowitz JB, Henschen-Edman AH, Coates AI, Hantgan RR, Lord ST. The impaired polymerization of fibrinogen Longmont (Bbeta166Arg-->Cys) is not improved by removal of disulfide-linked dimers from a mixture of dimers and cysteine-linked monomers. Blood. 2001 Aug 01; 98(3):661-6.
    View in: PubMed
    Score: 0.002
  45. Huang TC, Jordan RE, Hantgan RR, Alevriadou BR. Differential effects of c7E3 Fab on thrombus formation and rt-PA-Mediated thrombolysis under flow conditions. Thromb Res. 2001 Jun 01; 102(5):411-25.
    View in: PubMed
    Score: 0.002
  46. Hockey KJ, Anderson RA, Cook VR, Hantgan RR, Weinberg RB. Effect of the apolipoprotein A-IV Q360H polymorphism on postprandial plasma triglyceride clearance. J Lipid Res. 2001 Feb; 42(2):211-7.
    View in: PubMed
    Score: 0.002
  47. Lounes KC, Lefkowitz JB, Coates AI, Hantgan RR, Henschen-Edman A, Lord ST. Fibrinogen Longmont. A heterozygous abnormal fibrinogen with B beta Arg-166 to Cys substitution associated with defective fibrin polymerization. Ann N Y Acad Sci. 2001; 936:129-32.
    View in: PubMed
    Score: 0.002
  48. Hantgan R, Fowler W, Erickson H, Hermans J. Fibrin assembly: a comparison of electron microscopic and light scattering results. Thromb Haemost. 1980 Dec 19; 44(3):119-24.
    View in: PubMed
    Score: 0.002
  49. Hogan KA, Gorkun OV, Lounes KC, Coates AI, Weisel JW, Hantgan RR, Lord ST. Recombinant fibrinogen Vlissingen/Frankfurt IV. The deletion of residues 319 and 320 from the gamma chain of firbinogen alters calcium binding, fibrin polymerization, cross-linking, and platelet aggregation. J Biol Chem. 2000 Jun 09; 275(23):17778-85.
    View in: PubMed
    Score: 0.002
  50. Tansey JT, Thuren TY, Jerome WG, Hantgan RR, Grant K, Waite M. Hydrolysis of phosphatidylcholine by hepatic lipase in discoidal and spheroidal recombinant high-density lipoprotein. Biochemistry. 1997 Oct 07; 36(40):12227-34.
    View in: PubMed
    Score: 0.002
  51. Endenburg SC, Hantgan RR, Lindeboom-Blokzijl L, Lankhof H, Jerome WG, Lewis JC, Sixma JJ, de Groot PG. On the role of von Willebrand factor in promoting platelet adhesion to fibrin in flowing blood. Blood. 1995 Dec 01; 86(11):4158-65.
    View in: PubMed
    Score: 0.002
  52. Carr ME, Carr SL, Hantgan RR, Braaten J. Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus. Thromb Haemost. 1995 Mar; 73(3):499-505.
    View in: PubMed
    Score: 0.002
  53. Webb CD, Hantgan RR, Byeff PD, Owen J. Fibrinogen New Britain: characterization of an A alpha Arg 16-->His variant human fibrinogen. Blood Coagul Fibrinolysis. 1994 Apr; 5(2):233-8.
    View in: PubMed
    Score: 0.001
  54. Endenburg SC, Hantgan RR, Sixma JJ, de Groot PG, Zwaginga JJ. Platelet adhesion to fibrin(ogen). Blood Coagul Fibrinolysis. 1993 Feb; 4(1):139-42.
    View in: PubMed
    Score: 0.001
  55. Hensler ME, Frojmovic M, Taylor RG, Hantgan RR, Lewis JC. Platelet morphologic changes and fibrinogen receptor localization. Initial responses in ADP-activated human platelets. Am J Pathol. 1992 Sep; 141(3):707-19.
    View in: PubMed
    Score: 0.001
  56. Lewis JC, Hantgan RR, Stevenson SC, Thornburg T, Kieffer N, Guichard J, Breton-Gorius J. Fibrinogen and glycoprotein IIb/IIIa localization during platelet adhesion. Localization to the granulomere and at sites of platelet interaction. Am J Pathol. 1990 Jan; 136(1):239-52.
    View in: PubMed
    Score: 0.001
  57. Knoll D, Hantgan R, Williams J, McDonagh J, Hermans J. Characterization of soluble polymerized fibrin formed in the presence of excess fibrinogen fragment D. Biochemistry. 1984 Jul 31; 23(16):3708-15.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.